<p>The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells</p>

Li Wang(University of Minnesota), Xiaoxia Liu(Sun Yat-sen University)
OncoTargets and Therapy
July 1, 2019
Cited by 76


Related Papers